ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
Ângelo Maiolino, Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael, K. Yong, Marcelo Capra, Thierry Façon, Roman Hájek, I. Spicka, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G Martin
Topics & Concepts
CarfilzomibDexamethasoneInterim analysisMedicineRefractory (planetary science)InterimMultiple myelomaOpen labelOncologyPharmacologyInternal medicineRandomized controlled trialLenalidomidePolitical scienceBiologyLawAstrobiologyMultiple Myeloma Research and TreatmentsResearch on Leishmaniasis StudiesSynthesis and Biological Evaluation